...
首页> 外文期刊>Circulation. Heart failure >Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
【24h】

Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.

机译:射血分数保留的心力衰竭患者的体重指数和不良心血管预后:厄贝沙坦治疗保留射血分数的心衰患者的结果(I-PRESERVE)。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Obesity is a major risk factor for incident heart failure (HF). Paradoxically, in HF with reduced left ventricular ejection fraction (HFREF), a high body mass index (BMI) appears to be beneficial. Approximately 50% of HF patients have a preserved left ventricular ejection fraction (HFPEF). However, there are few data regarding the relationship between BMI and outcomes in HFPEF. METHODS AND RESULTS: Baseline characteristics and cardiovascular outcomes were assessed in the 4109 patients (mean age, 72 years; mean follow-up, 49.5 months) in the Irbesartan in HF with Preserved Ejection Fraction (I-PRESERVE) trial. Based on the BMI distribution, 5 BMI categories were defined: <23.5, 23.5 to 26.4, 26.5 to 30.9, 31 to 34.9, and >/=35 kg/m(2). Most patients (71%) had a BMI >/=26.5, 21% had a BMI between 23.5 and 26.4, and 8% had a BMI <23.5 kg/m(2). Patients with higher BMI were younger, more often women, and more likely to have hypertension and diabetes and higher left ventricular ejection fraction. Patients with BMI of 26.5 to 30.9 kg/m(2) had the lowest rate for the primary composite outcome (death or cardiovascular hospitalization) and were used as reference group. After adjustment for 21 risk variables including age, sex, and N-terminal pro-brain natriuretic peptide, the hazard ratio for the primary outcome was increased in patients with BMI <23.5 (hazard ratio, 1.27; 95% confidence interval, 1.04 to 1.56; P=0.019) and in those with BMI >/=35 kg/m(2) (hazard ratio, 1.27; 95% confidence interval, 1.06 to 1.52; P=0.011) compared with the referent group. A similar relationship was found for all-cause mortality and for HF hospitalization. CONCLUSIONS: Obesity is common in HFPEF patients and is accompanied by multiple differences in clinical characteristics. Independent of other key prognostic variables, there was a U-shaped relationship, with the greatest rate of adverse outcomes in the lowest and highest BMI categories. CLINICAL TRIAL REGISTRATION- URL: http://www.clinicaltrials.gov. Unique identifier: NCT000095238.
机译:背景:肥胖是发生心力衰竭(HF)的主要危险因素。矛盾的是,在HF左室射血分数(HFREF)降低的情况下,高体重指数(BMI)似乎是有益的。大约50%的HF患者左心室射血分数(HFPEF)保持不变。但是,关于HFPEF中BMI与结局之间关系的数据很少。方法和结果:厄贝沙坦HF保留射血分数(I-PRESERVE)试验的4109例患者(平均年龄72岁;平均随访49.5个月)评估了基线特征和心血管结局。根据BMI分布,定义了5种BMI类别:<23.5、23.5至26.4、26.5至30.9、31至34.9和> / = 35 kg / m(2)。大多数患者(71%)的BMI> / = 26.5,21%的BMI在23.5至26.4之间,8%的BMI <23.5 kg / m(2)。 BMI较高的患者较年轻,女性较多,并且更有可能患有高血压和糖尿病以及左心室射血分数较高。 BMI为26.5至30.9 kg / m(2)的患者发生主要复合终点(死亡或心血管疾病住院)的发生率最低,被用作参考组。在调整了年龄,性别和N末端脑钠肽前体这21个风险变量后,BMI <23.5的患者主要结局的危险比增加(危险比1.27; 95%置信区间1.04至1.56) ; P = 0.019)和BMI> / = 35 kg / m(2)(危险比为1.27; 95%置信区间为1.06至1.52; P = 0.011)。在全因死亡率和心衰住院方面也发现了类似的关系。结论:肥胖症在HFPEF患者中很常见,并伴有多种临床特征差异。与其他关键预后变量无关,存在U型关系,在最低和最高BMI类别中不良反应发生率最高。临床试验注册-URL:http://www.clinicaltrials.gov。唯一标识符:NCT000095238。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号